ClinicalTrials.gg
RecruitingNCT07497269Updated Oct 28, 2026

Conventional vs Pulsed RF in Coccydynia

An interventional study of Pulsed Radiofrequency and Conventional Radiofrequency in Back Pain, sponsored by Adana City Training and Research Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Adana City Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Back Pain with a site in Turkey — 9 open to participants now, 11 under way, none of them phase 3. Back Pain · Turkey.

Planned enrollment
6th of 34
90 · median 55
Started
2026
with 3 others
No phase
33 of 57
5 open now
Primary completion
2027-04
later than 8 of 10 live
Registered
51st of 57
by date

Among the 57 studies in Back Pain with a site in Turkey, this one is the 6th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 33 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 51st registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 110 are open to participants now.

Browse Back Pain studies →

Open to participants now

9 of the 57 studies in Back Pain with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Back Pain with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to prospectively evaluate the effects of pulsed and conventional radiofrequency ablation of the ganglion impar on pain, quality of life, and sleep quality in patients with refractory coccydynia, and to determine whether one treatment is superior to the other.

Read the detailed description

Coccydynia, commonly referred to as tailbone pain, is a persistent pain condition targeting the coccyx, a small triangular bone located at the lower end of the spine. The main cause of this pain is usually abnormal movement in the coccygeal region, which leads to continuous inflammation. Coccydynia more commonly affects women than men and is often associated with obesity. Although it most frequently occurs around the age of 40, it can be seen in individuals of all ages. The origins of coccydynia are varied, including both physical and psychological factors. The main physical causes are trauma from falling onto the buttocks, repetitive minor injuries, or childbirth, which are the most common triggers. Non-traumatic causes of coccydynia include degenerative diseases of the joints or discs, abnormal movements in the sacrococcygeal joint, obesity, infections, changes in the shape of the coccyx, or cancers in the pelvic or anorectal regions. The effectiveness of treatments for coccydynia varies considerably.

Several conservative treatment options exist for coccydynia, such as nonsteroidal anti-inflammatory drugs (NSAIDs), local analgesics, hot or cold applications, transcutaneous electrical nerve stimulation (TENS), specially designed wedge-shaped cushions (coccygeal cushions), and exercises aimed at relaxing the levator ani muscle. These methods aim to reduce pain and inflammation and improve the functionality of the coccyx and surrounding muscles. When these conservative approaches fail to provide relief, more invasive procedures may be considered. Techniques such as direct local anesthetic injections to the coccyx, coccygeal nerve blocks, caudal epidural injections, and ganglion impar blocks offer minimally invasive alternatives for coccydynia treatment. Among the methods for impar ganglion blocks, pulsed RF, thermocoagulation ablation techniques, and neurolytic techniques are considered treatments that provide long-term pain palliation. The transacrococcygeal technique for impar ganglion block is an easy and safe method. This technique allows neurolysis or radiofrequency thermocoagulation ablation of the impar ganglion and can be used for diagnostic blocks depending on the response to initial diagnostic injections.

The ganglion impar (Walther ganglion) is a single sympathetic ganglion formed by the convergence of the distal ends of the lumbosacral sympathetic chains. It is the lowest ganglion of the sympathetic nervous system. Being single and medial (unlike the paired paravertebral sympathetic ganglia), it is the only solitary sympathetic ganglion. It is located retroperitoneally, anterior to the sacrum, at the level of the sacrococcygeal symphysis, and posterior to the rectum. It provides sympathetic efferent fibers and receives afferent sensory information from many pelvic structures, supplying sympathetic and nociceptive innervation to the perineum, coccyx, anus, distal rectum, vulva, urethra, and vagina. Interventions on the ganglion impar disrupt afferent sympathetic and nociceptive pathways from the pelvis, perineum, and anal region. Interventions on the ganglion impar can be performed using various agents and techniques, including local anesthetics, corticosteroids, ethanol, phenol, botulinum toxin, radiofrequency ablation (RFA) or modulation (RFM), and cryoablation. The transsacrococcygeal technique is more commonly used. Numerous technique variations exist, but the goal is to successfully direct the needle to the anterior surface of the coccyx or sacrococcygeal symphysis to deliver local anesthetics, steroids, or neurolytic agents without damaging pelvic bones or organs. Radiopaque contrast is injected to visualize proper retroperitoneal distribution of the agent along the anterior surface of the coccyx.

Visceral pain mediated by sympathetic fibers in the perineal region can be effectively treated by neurolysis of the impar ganglion. Theoretically, this procedure can also be applied for pain due to malignancy, endometriosis, complex regional pain syndrome, prostate pain, radiation-induced enteritis, postherpetic neuralgia, and refractory coccydynia. The use of sympathetic chain ablation for persistent pain in the sacral-pelvic region differs from other targets, because the anatomical variation of the impar ganglion requires careful combination of radiofrequency thermocoagulation and neurolytic agents (alcohol or phenol) to maximize pain control. When using the thermocoagulation radiofrequency ablation technique, special equipment such as electrostimulation devices and minute controllers are required. Therefore, selective destruction of nerve fibers is possible, and the size and location of the lesion can be controlled, resulting in a lower risk of complications.

The effects of conventional radiofrequency (CRF) thermocoagulation for chronic coccydynia were retrospectively analyzed (patients unresponsive to conservative treatment and local injections for 6 months. Ten patients who responded to diagnostic block with 10 mL of 0.25% bupivacaine underwent CRF treatment. Approximately 90% of patients achieved successful results at 6 months, defined as a 50% reduction in VAS scores. Transcoccygeal/intercoccygeal CRF of the ganglion impar is simple, relatively safe, and should be considered for chronic coccydynia unresponsive to conservative therapy for 6 months. Similar findings were observed by another study in a retrospective analysis of CRF in 20 patients with chronic refractory coccydynia.

No previous study has compared the superiority of these two routinely applied long-term coccyx pain treatments.

03

Conditions studied

  • Back Pain

Keywords

  • Radiofrequency Ablation
  • low back pain
  • quality of life
  • coccyx
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years.
  • Chronic pain in the coccygeal region lasting longer than 3 months, unresponsive to analgesics, anti-inflammatory drugs, and other conservative treatment methods.
  • Patients scheduled to undergo ganglion impar treatment with either conventional or pulsed radiofrequency ablation (RFA).

Exclusion criteria

Exclusion Criteria:

  • Incomplete medical records.
  • Loss to follow-up.
  • Technical failure during the block procedure.
  • Local infection, bleeding disorders, allergy to contrast agents, or history of spinal surgery.
  • History of .
  • Refusal to participate in the study.
  • Diagnosed psychological disorders.
  • Individuals unable to communicate effectively or understand instructions.
  • Age under 18 or over 80 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Pulse RF Group

    Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Pulsed RFA is applied at 42 °C for 4 minutes. Pulsed RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure

    Procedure: Pulsed Radiofrequency

  • Active comparator
    Conventional RF Group

    Conventional RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Conventional RFA is applied for two cycles of 90 seconds at 80 °C.

    Procedure: Conventional Radiofrequency

Interventions

  • ProcedurePulsed Radiofrequency

    Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Pulsed RFA is applied at 42 °C for 4 minutes after stimulation.

  • ProcedureConventional Radiofrequency

    Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Neuroablation is applied for 2 cycles of 90 seconds at 80 °C.

06

What researchers measure

Primary outcomes

  1. The Numeric Rating Scale (NRS)

    Pain intensity was assessed using the Numeric Rating Scale (NRS), a linear pain scale ranging from 0 (no pain) to 10 (the worst imaginable pain)."

    Time frame: From enrollment to the end of treatment at 12th months

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    Oswestry Disability Index (ODI): The ODI is a self-reported measure used to assess the extent to which a patient's daily activities are limited. It is one of the most commonly used tools in clinical research and routine patient follow-up to determine the level of functional disability. General Characteristics: The index consists of 10 sections, each scored from 0 to 5 (0: no difficulty, 5: maximum difficulty). The maximum raw score is 50, and the total score is multiplied by 2 to convert it to a percentage (0-100%). Assessment Categories (approximate): 0-20%: Minimal disability (the patient can continue daily activities and perform most tasks). 21-40%: Moderate disability. 41-60%: Severe disability (pain significantly affects daily life). 61-80%: Crippling disability (the patient is unable to perform many activities). 81-100%: Bed-bound or completely dependent, unable to maintain an active lifestyle.

    Time frame: From enrollment to the end of treatment at 12th months

  2. Pittsburgh Sleep Quality Index (PSQI)

    Pittsburgh Sleep Quality Index (PSQI): The PSQI includes 18 items that contribute to its scoring. It assesses seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Some components are represented by a single item, while others are calculated by grouping several items. Each item is scored from 0 to 3, and the sum of the seven component scores forms the total PSQI score. The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. A total PSQI score of ≤5 indicates "good sleep quality," whereas a score \>5 indicates "poor sleep quality."

    Time frame: From enrollment to the end of treatment at 12 months

  3. Global Perceived Effect (GPE)

    Global Perceived Effect (GPE): The GPE measures the patient's perception of their condition compared to a previous period. It reflects the response to the question: "How do you feel now compared to before treatment?" At 1, 3, 6, and 12 months after treatment, the patient's overall perceived effect will be assessed using a 7-point Likert scale: 1. \- Much worse 2. \- Worse 3. \- Slightly worse 4. \- No change 5. \- Slightly better 6. \- Better 7. \- Much better Patients reporting "much better" (score = 7) or "better" (score = 6) will be considered satisfied with the procedure.

    Time frame: From enrollment to the end of treatment at 12th months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • 1-Adas, C., Ozdemir, U., Toman, H., Luleci, N., Luleci, E., & Adas, H. (2016). Transsacrococcygeal approach to ganglion impar: radiofrequency application for the treatment of chronic intractable coccydynia. Journal of pain research, 1173-1177. 2-Romanukha, D. M., & Biloshytsky, V. V. (2024). Minimally Invasive Interventions on Ganglion Impar in Treatment of Patients with Coccygodynia. Ukr Neurosurg J, 1, 43-52. 3-Nasiri, A., Vajari, F. F., Sane, S., & Afsargharehbagh, R. (2024). Assessment of ganglion impar block effect on treatment results of coccydynia: a cross-sectional study. Anesthesiology and Pain Medicine, 14(2), e142137. 4-Turchan, A., Fahmi, A., & Subianto, H. (2018). Impar ganglion block with combination of neurolysis drugs and radiofrequency thermocoagulation for perineal pain. Asian Journal of Neurosurgery, 13(03), 838-841. 5-Gupta, M., & Das, G. (2020). Ganglion Impar block and neurolysis for chronic pain: A review. Journal on Musculoskeletal Ultrasound and Pain Medicine, 6(1), 24-28. 6-Usmani H, Dureja GP, Andleeb R, Tauheed N, Asif N. Conventional Radiofrequency Thermocoagulation vs Pulsed Radiofrequency Neuromodulation of Ganglion Impar in Chronic Perineal Pain of Nononcological Origin. Pain Med.2018;19(12):2348-2356. doi:10.1093/pm/pnx244. PMID: 29329442)

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared to ensure the confidentiality and privacy of the patients, in accordance with ethical approval and local regulations

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 259 non-industry interventional studies with no phase under Back Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 33. This study's planned 12 months is close to that.

Counting every sponsor, half of 294 studies reached it within 13 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 27, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)no status→Recruiting
  • Tobb Etü Hospital · Ankara, Turkey (Türkiye)no status→Recruiting
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Adana City Training and Research Hospital · Adana, Turkey (Türkiye)no status→Recruiting
    • Tobb Etü Hospital · Ankara, Turkey (Türkiye)no status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07497269
Lead sponsor
Adana City Training and Research Hospital
Responsible party
Derya Bayram (Medical Doctor, Adana City Training and Research Hospital) — Principal investigator
First posted
Mar 27, 2026
Start date
Apr 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Derya Bayram, MD
Contact
deryak.bayram@gmail.com
+905433400430
Dostali Aliyev, MD
Contact
dr.dostalialiyev@gmail.com
+905514351936
Derya Bayram, MD
principal investigator · Adana City Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion